MedTrace Logo

Ranibizumab for Neovascularization in Sickle Cell Retinopathy

NCT00618644 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2012-09-27

No results posted yet for this study

Summary

The purpose of this study is to determine the ocular and non-ocular safety of a single dose of ranibizumab in treating neovascularization secondary to sickle cell retinopathy.

Conditions

Interventions

DRUG

Ranibizumab

Ranibizumab 0.5 mg intravitreal injection

Sponsors & Collaborators

  • Wayne State University

    collaborator OTHER

  • Genentech, Inc.

    collaborator INDUSTRY

  • Kresge Eye Institute

    lead OTHER

Principal Investigators

  • Vinay Shah, MD · Kresge Eye Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00618644 on ClinicalTrials.gov